Cancer Immunotherapy and the Application of In Vitro Immunoassays in Drug Development
The spectrum of treatment modalities for cancer immunotherapy has expanded greatly, and now includes the use of antibodies, immune stimulation, cancer vaccines, adoptive T cell transfer, immune checkpoint inhibitors, and oncolytic virus therapies.
Join experts from Nimbus Therapeutics, Phillip Morris International and WuXi AppTec to review multiple immunology assays that enable the exploration of the function of a variety of immune cells including T cells, B cells, NK cells, and macrophages.
Date: Wednesday, December 09, 2020
Time: 17:00 – 18:15 CET (11:00 AM Eastern Standard Time)
READ MORE & SIGN UP
Through case studies, we will discuss the importance of interrogating the stimulation, differentiation, and suppression of immune cells, and also the interaction between immune system components and cancer cells.
Lastly, we will review the WuXi AppTec immunology platform and its application for the evaluation of drug efficacy in preclinical research.
- Cancer Immunotherapy Background and Development
- Mechanism of the Immune System in Tumorigenesis
- Utilizing the WuXi AppTec In Vitro Immunology Platform to advance immuno-oncology drug discovery
Senior Vice President, Head of Biology
Dr. Christine Loh is Senior Vice President, Head of Biology at Nimbus. Prior to joining Nimbus, she served as Vice President of Translational Medicine at Kymera Therapeutics, where she facilitated biomarker strategy, patient selection and resource-building initiatives to transition pipeline programs into clinical development. Previously, Christine was the Executive Director of Research at Bioverativ, leading a group focused on hemophilia and sickle cell disease. During that time, she also helped progress the spinout of Bioverativ from Biogen, where she had spent five years directing rare disease and immunology research. Christine also has over 20 years of experience as a lead researcher at Sirtris, Pfizer and ICOS Corporation, advancing several programs from concept to IND in autoimmunity, oncology and metabolic disease. She has a B.S. in biochemistry from Wellesley College and a Ph.D. in immunology from the Division of Medical Sciences at Harvard University.
High Content Screening Manager
Phillip Morris International
Diego Marescotti is the High Content Screening Manager in the System Toxicology department of Philip Morris International R&D. After completing his PhD in Oncology and Molecular Pharmacology, at the University of Ferrara (Italy) he continued his research in the tumor immunology field. He joined Philip Morris International in 2012 bringing his knowledge for cell biology and imaging to contribute to set up the Cellular Research Lab. Since then he is leading a team of researchers who perform compound profiling with high-throughput systems.